BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 20457269)

  • 1. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study.
    Prasad VK; Lucas KG; Kleiner GI; Talano JA; Jacobsohn D; Broadwater G; Monroy R; Kurtzberg J
    Biol Blood Marrow Transplant; 2011 Apr; 17(4):534-41. PubMed ID: 20457269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients.
    Kurtzberg J; Prockop S; Teira P; Bittencourt H; Lewis V; Chan KW; Horn B; Yu L; Talano JA; Nemecek E; Mills CR; Chaudhury S
    Biol Blood Marrow Transplant; 2014 Feb; 20(2):229-35. PubMed ID: 24216185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
    Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.
    Lazarus HM; Koc ON; Devine SM; Curtin P; Maziarz RT; Holland HK; Shpall EJ; McCarthy P; Atkinson K; Cooper BW; Gerson SL; Laughlin MJ; Loberiza FR; Moseley AB; Bacigalupo A
    Biol Blood Marrow Transplant; 2005 May; 11(5):389-98. PubMed ID: 15846293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population.
    Lucchini G; Introna M; Dander E; Rovelli A; Balduzzi A; Bonanomi S; Salvadè A; Capelli C; Belotti D; Gaipa G; Perseghin P; Vinci P; Lanino E; Chiusolo P; Orofino MG; Marktel S; Golay J; Rambaldi A; Biondi A; D'Amico G; Biagi E
    Biol Blood Marrow Transplant; 2010 Sep; 16(9):1293-301. PubMed ID: 20350611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-engraftment syndrome after unrelated donor umbilical cord blood transplantation in patients with hematologic malignancies.
    Wang X; Liu H; Li L; Geng L; Ding K; Liu X; Tong J; Zhu W; Sun Z
    Eur J Haematol; 2012 Jan; 88(1):39-45. PubMed ID: 21933279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias.
    Carella AM; Lerma E; Dejana A; Corsetti MT; Celesti L; Bruni R; Benvenuto F; Figari O; Parodi C; Carlier P; Florio G; Lercari G; Valbonesi M; Casarino L; De Stefano F; Geniram A; Venturino M; Tedeschi L; Palmieri G; Piaggio G; Podestà M; Frassoni F; Van Lint MT; Marmont AM; Bacigalupo A
    Haematologica; 1998 Oct; 83(10):904-9. PubMed ID: 9830799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease.
    Sánchez-Guijo F; Caballero-Velázquez T; López-Villar O; Redondo A; Parody R; Martínez C; Olavarría E; Andreu E; Prósper F; Díez-Campelo M; Regidor C; Villaron E; López-Corral L; Caballero D; Cañizo MC; Pérez-Simon JA
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1580-5. PubMed ID: 24952358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single centre experience with allogeneic stem cell transplantation for severe aplastic anaemia in childhood.
    Ladenstein R; Peters C; Minkov M; Emminger-Schmidmeier W; Mann G; Höcker P; Hawliczek R; Rosenmayr A; Fink FM; Niederwieser D; Gadner H
    Klin Padiatr; 1997; 209(4):201-8. PubMed ID: 9293451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute gastrointestinal graft-versus-host disease in pediatric patients: serum albumin on day 5 from initiation of therapy correlates with nonrelapse mortality and overall survival.
    Goussetis E; Paisiou A; Kitra V; Peristeri I; Vessalas G; Stefanaki K; Panayotou I; Giamaiou K; Kontou E; Kitzoni M; Dimopoulou MN; Karkelis S; Kafritsa Y; Rapsomaniki E; Papassotiriou I; Tsirigotis P; Roma E; Graphakos S
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1058-66. PubMed ID: 21073975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].
    Sun J; Meng FY; Liu QF; Xu D; Xu B; Liu XL
    Ai Zheng; 2003 Dec; 22(12):1321-4. PubMed ID: 14693060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody.
    Kobbe G; Schneider P; Rohr U; Fenk R; Neumann F; Aivado M; Dietze L; Kronenwett R; Hünerlitürkoglu A; Haas R
    Bone Marrow Transplant; 2001 Jul; 28(1):47-9. PubMed ID: 11498743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation.
    Zhao K; Lou R; Huang F; Peng Y; Jiang Z; Huang K; Wu X; Zhang Y; Fan Z; Zhou H; Liu C; Xiao Y; Sun J; Li Y; Xiang P; Liu Q
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):97-104. PubMed ID: 25300866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
    Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
    Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults.
    Gonzalo-Daganzo R; Regidor C; Martín-Donaire T; Rico MA; Bautista G; Krsnik I; Forés R; Ojeda E; Sanjuán I; García-Marco JA; Navarro B; Gil S; Sánchez R; Panadero N; Gutiérrez Y; García-Berciano M; Pérez N; Millán I; Cabrera R; Fernández MN
    Cytotherapy; 2009; 11(3):278-88. PubMed ID: 19308773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological reconstitution and correlation of circulating serum inflammatory mediators/cytokines with the incidence of acute graft-versus-host disease during the first 100 days following unrelated umbilical cord blood transplantation.
    Abu-Ghosh A; Goldman S; Slone V; van de Ven C; Suen Y; Murphy L; Sender L; Cairo M
    Bone Marrow Transplant; 1999 Sep; 24(5):535-44. PubMed ID: 10482939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
    Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.